Tweets
The Rapidly Evolving Landscape of Cellular and Immune-based Therapies
When Henry Ford unveiled the Model T in 1908, the automobile industry was forever changed. A similar transformation is now underway in rheumatology, where cellular and immune therapies are redefining how we https://t.co/RQuVETSTG4
Dr. John Cush @RheumNow ( View Tweet )
6 months 3 weeks ago
💬 #ACR25 Topic Panels — LIVE!
Nov. 3 join RheumNow at 7 PM ET for a deep dives into the hottest topics in rheumatology:
👉 RA
Join Us Live on:
X • Facebook • YouTube • LinkedIn • https://t.co/V10S4oVFsv
Top experts. Real clinical insight. Don't miss these discussions https://t.co/i5UM0OBu86
Links:
Dr. John Cush @RheumNow ( View Tweet )
6 months 3 weeks ago
#ACR25 - Day 1 Report
https://t.co/JayJCP9Rue https://t.co/B62mKbW4B8
Dr. John Cush @RheumNow ( View Tweet )
6 months 3 weeks ago
"Personally I'm always ready to learn, although I do not always like being taught."
– Winston Churchill
Dr. John Cush @RheumNow ( View Tweet )
6 months 3 weeks ago
Catching AxSpA Early: Closing the Diagnostic Gap
Dr. Akhil Sood reports on abstract 2635 and abstract 2636 presented at #ACR25.
https://t.co/TmJQKQUu9E https://t.co/6dWf8DY2W3
Dr. John Cush @RheumNow ( View Tweet )
6 months 3 weeks ago
RA: Inject the Steroids
Dr. Richard Conway reports on abstract 1355, "Use of parenteral compared to oral glucocorticoids in early rheumatoid arthritis is superior for chance of being off steroids and escalation of therapy at 1 year," presented at the #ACR25. https://t.co/xFQMIpi75S
Dr. John Cush @RheumNow ( View Tweet )
6 months 3 weeks ago
#ACR25 Best Abstracts - Day 1
The RheumNow Faculty have run through day one at ACR25 and come with a few of their favorites - some what you expect, but some of these are gems.
https://t.co/tYY5xGOEGU https://t.co/wpQbvEcH1f
Dr. John Cush @RheumNow ( View Tweet )
6 months 3 weeks ago
New Gout Therapies Show Promise in Phase III Trials
At #ACR25, the American College of Rheumatology’s annual meeting, researchers presented pivotal Phase III studies highlighting novel therapeutic options for patients with gout, particularly those with limited treatment choices https://t.co/Ff16L2CHc0
Dr. John Cush @RheumNow ( View Tweet )
6 months 3 weeks ago
#ACR25 Sheds Light on Disparities, Age-Related Trends, and Epidemiology in Autoimmune Rheumatic Diseases At #ACR25, new research explored critical disparities and epidemiologic trends shaping outcomes in autoimmune rheumatic diseases across diverse populations and age groups. https://t.co/CPob0ppjv3
Dr. John Cush @RheumNow ( View Tweet )
6 months 3 weeks ago
💬 #ACR2025 Topic Panels — LIVE!
Nov. 2 join RheumNow at 7 PM ET for a deep dives into the hottest topics in rheumatology:
👉 PsA
Join Us Live on:
X Live • Facebook Live • YouTube Live • LinkedIn Live • https://t.co/V10S4oVFsv
Top experts. Real clinical insight. Don't miss https://t.co/A4pUjZG3Dr
Links:
Dr. John Cush @RheumNow ( View Tweet )
6 months 3 weeks ago
Upadacitinib is a Double Edged Vascular Sword in GCA
Dr. David Liew discusses abstracts O751, O738, and O734 presented at #ACR25.
https://t.co/eTmVehP2Cd https://t.co/vxehwRWM2D
Dr. John Cush @RheumNow ( View Tweet )
6 months 4 weeks ago
Hospitalization in Stills: Is it "Still" an infection?
Dr. Janet Pope discusses abstract 0163, "Trends in hospitalization and outcomes among patients admitted with Adult-onset Still’s disease in the United States: INSIGHTS FROM THE NATIONAL INPATIENT SAMPLE (2016-2022)," https://t.co/3Z0U9XN3nx
Dr. John Cush @RheumNow ( View Tweet )
6 months 4 weeks ago


